Growth prospects remain strong for Pfizer

27-08-2014 Seeking AlphaComments (0)

Business FinanceBusiness FinanceDow Jones Industrial AverageHealth Medical PharmaHealth Medical Pharma

By IAEResearch:

The healthcare sector has been performing well over the last few months - in fact, most of the BioPharma companies have outperformed most of the sectors and the overall market itself. However, some of the major players have not been able to show the same price movement - Pfizer (NYSE:PFE) is one example as the stock has been performing poorly. Over the last six months, the stock has lost over 8%.

Over the last two years, Pfizer has spun-off several of its business segments including Animal Health, Nutrition and Capsugel businesses, in order to support its growth-via-acquisition strategy. These changes have allowed Pfizer to improve its cash position, which is vital for the strategic growth plans of the company in the long run. These transactions also resulted in better profitability for the company in 2013, clearly showing that the company was getting rid of less-profitable segments of the business. The


Complete Story »

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top